Merck and Eisai discontinue research on late-stage skin cancer

Published Date: 11 Apr 2023

Merck and Eisai said on Friday they are discontinuing the late-stage trial of Keytruda and Lenvim for the treatment of adults with inoperable or metastatic melanoma.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Global inequalities found in cancer research funding

2.

Breast cancer surgery: Study finds overnight hospital stay not important for older patients

3.

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

4.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

5.

Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot